Identification of the Oncogenic Role of MSH2 in the Stemness and Progression of Glioma Through Regulating Wnt Signaling Pathway

ABSTRACT Background Glioma is one of the most aggressive brain tumors, and its progression is often associated with stemness maintenance and therapy resistance. The role of MSH2 in glioma remains largely unclear. Methods We analyzed public datasets and clinical samples to assess MSH2 expression and...

Full description

Saved in:
Bibliographic Details
Main Authors: Jun Liu, Jiayu Chen, Lianglei Jiang
Format: Article
Language:English
Published: Wiley 2025-07-01
Series:Cancer Medicine
Subjects:
Online Access:https://doi.org/10.1002/cam4.70993
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849247164775006208
author Jun Liu
Jiayu Chen
Lianglei Jiang
author_facet Jun Liu
Jiayu Chen
Lianglei Jiang
author_sort Jun Liu
collection DOAJ
description ABSTRACT Background Glioma is one of the most aggressive brain tumors, and its progression is often associated with stemness maintenance and therapy resistance. The role of MSH2 in glioma remains largely unclear. Methods We analyzed public datasets and clinical samples to assess MSH2 expression and its clinical relevance. Functional assays in vitro and in vivo were performed to investigate the effects of MSH2 knockdown on glioma cell behavior. Mechanistic studies were conducted to explore downstream signaling pathways and stemness regulation. Results MSH2 was found to be significantly upregulated in glioma tissues and cell lines, and its high expression correlated with poor prognosis. Silencing MSH2 inhibited cell proliferation, migration, and tumor growth, while promoting apoptosis and G2 cell cycle arrest. Mechanistically, phospho‐kinase screening and rescue experiments suggested that MSH2 promotes glioma progression via activation of the Wnt/β‐catenin signaling pathway. Furthermore, MSH2 knockdown suppressed the expression of stemness markers, impaired sphere formation, and sensitized glioma cells to cisplatin treatment. Conclusions Our study identifies MSH2 as an oncogenic factor in glioma, which drives stemness and progression through regulation of the Wnt/β‐catenin pathway, and may serve as a potential therapeutic target.
format Article
id doaj-art-49eaa6fc10d445c5bd5753a12507a32c
institution Kabale University
issn 2045-7634
language English
publishDate 2025-07-01
publisher Wiley
record_format Article
series Cancer Medicine
spelling doaj-art-49eaa6fc10d445c5bd5753a12507a32c2025-08-20T03:58:18ZengWileyCancer Medicine2045-76342025-07-011413n/an/a10.1002/cam4.70993Identification of the Oncogenic Role of MSH2 in the Stemness and Progression of Glioma Through Regulating Wnt Signaling PathwayJun Liu0Jiayu Chen1Lianglei Jiang2Department of Neurosurgery, Taihe Hospital Hubei University of Medicine Shiyan Hubei ChinaDepartment of Information Resources, Taihe Hospital Hubei University of Medicine Shiyan Hubei ChinaDepartment of Neurosurgery Wuhan Union Hospital Wuhan Hubei ChinaABSTRACT Background Glioma is one of the most aggressive brain tumors, and its progression is often associated with stemness maintenance and therapy resistance. The role of MSH2 in glioma remains largely unclear. Methods We analyzed public datasets and clinical samples to assess MSH2 expression and its clinical relevance. Functional assays in vitro and in vivo were performed to investigate the effects of MSH2 knockdown on glioma cell behavior. Mechanistic studies were conducted to explore downstream signaling pathways and stemness regulation. Results MSH2 was found to be significantly upregulated in glioma tissues and cell lines, and its high expression correlated with poor prognosis. Silencing MSH2 inhibited cell proliferation, migration, and tumor growth, while promoting apoptosis and G2 cell cycle arrest. Mechanistically, phospho‐kinase screening and rescue experiments suggested that MSH2 promotes glioma progression via activation of the Wnt/β‐catenin signaling pathway. Furthermore, MSH2 knockdown suppressed the expression of stemness markers, impaired sphere formation, and sensitized glioma cells to cisplatin treatment. Conclusions Our study identifies MSH2 as an oncogenic factor in glioma, which drives stemness and progression through regulation of the Wnt/β‐catenin pathway, and may serve as a potential therapeutic target.https://doi.org/10.1002/cam4.70993drug sensitivitygliomaMSH2tumor development
spellingShingle Jun Liu
Jiayu Chen
Lianglei Jiang
Identification of the Oncogenic Role of MSH2 in the Stemness and Progression of Glioma Through Regulating Wnt Signaling Pathway
Cancer Medicine
drug sensitivity
glioma
MSH2
tumor development
title Identification of the Oncogenic Role of MSH2 in the Stemness and Progression of Glioma Through Regulating Wnt Signaling Pathway
title_full Identification of the Oncogenic Role of MSH2 in the Stemness and Progression of Glioma Through Regulating Wnt Signaling Pathway
title_fullStr Identification of the Oncogenic Role of MSH2 in the Stemness and Progression of Glioma Through Regulating Wnt Signaling Pathway
title_full_unstemmed Identification of the Oncogenic Role of MSH2 in the Stemness and Progression of Glioma Through Regulating Wnt Signaling Pathway
title_short Identification of the Oncogenic Role of MSH2 in the Stemness and Progression of Glioma Through Regulating Wnt Signaling Pathway
title_sort identification of the oncogenic role of msh2 in the stemness and progression of glioma through regulating wnt signaling pathway
topic drug sensitivity
glioma
MSH2
tumor development
url https://doi.org/10.1002/cam4.70993
work_keys_str_mv AT junliu identificationoftheoncogenicroleofmsh2inthestemnessandprogressionofgliomathroughregulatingwntsignalingpathway
AT jiayuchen identificationoftheoncogenicroleofmsh2inthestemnessandprogressionofgliomathroughregulatingwntsignalingpathway
AT liangleijiang identificationoftheoncogenicroleofmsh2inthestemnessandprogressionofgliomathroughregulatingwntsignalingpathway